Gino Santini Sells 5,405 Shares of Collegium Pharmaceutical (NASDAQ:COLL) Stock

Key Points

• Gino Santini, a director at Collegium Pharmaceutical, sold 5,405 shares of stock at an average price of $37.19, totaling approximately $201,000, which represents a 5.38% decrease in his ownership.
• Collegium Pharmaceutical's board approved a stock repurchase program allowing the company to buy back $150 million of its outstanding shares, signaling that they believe the stock is undervalued.
• Several analysts upgraded Collegium Pharmaceutical's stock ratings, including a "strong-buy" rating from HC Wainwright with a price target of $44.00.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) Director Gino Santini sold 5,405 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $37.19, for a total value of $201,011.95. Following the completion of the sale, the director owned 95,042 shares in the company, valued at $3,534,611.98. This trade represents a 5.38% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Collegium Pharmaceutical Price Performance

Shares of COLL stock traded down $0.41 on Friday, reaching $39.11. The company's stock had a trading volume of 447,830 shares, compared to its average volume of 413,800. The company has a quick ratio of 1.10, a current ratio of 1.18 and a debt-to-equity ratio of 3.27. Collegium Pharmaceutical, Inc. has a 12-month low of $23.23 and a 12-month high of $42.29. The company has a market capitalization of $1.23 billion, a P/E ratio of 37.61 and a beta of 0.68. The stock's 50 day simple moving average is $32.42 and its 200-day simple moving average is $30.05.

Collegium Pharmaceutical announced that its board has authorized a share buyback plan on Monday, July 7th that permits the company to buyback $150.00 million in outstanding shares. This buyback authorization permits the specialty pharmaceutical company to reacquire up to 15.4% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on COLL. HC Wainwright upgraded Collegium Pharmaceutical to a "strong-buy" rating and set a $44.00 price target on the stock in a research report on Monday, August 11th. Piper Sandler restated a "neutral" rating and set a $37.00 price target (up previously from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. Finally, Wall Street Zen upgraded Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 9th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, Collegium Pharmaceutical currently has an average rating of "Buy" and an average price target of $42.33.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Rubric Capital Management LP increased its holdings in shares of Collegium Pharmaceutical by 5.3% in the second quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company's stock worth $93,374,000 after buying an additional 157,743 shares during the period. Fuller & Thaler Asset Management Inc. increased its holdings in shares of Collegium Pharmaceutical by 1.4% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,371,448 shares of the specialty pharmaceutical company's stock worth $40,938,000 after buying an additional 19,568 shares during the period. Emerald Advisers LLC increased its holdings in shares of Collegium Pharmaceutical by 1.3% in the second quarter. Emerald Advisers LLC now owns 837,549 shares of the specialty pharmaceutical company's stock worth $24,766,000 after buying an additional 11,074 shares during the period. Geode Capital Management LLC increased its holdings in shares of Collegium Pharmaceutical by 1.9% in the second quarter. Geode Capital Management LLC now owns 780,243 shares of the specialty pharmaceutical company's stock worth $23,075,000 after buying an additional 14,709 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its holdings in shares of Collegium Pharmaceutical by 18.1% in the first quarter. Massachusetts Financial Services Co. MA now owns 713,854 shares of the specialty pharmaceutical company's stock worth $21,309,000 after buying an additional 109,655 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.